David J. Bearss

GLP-1 AGONISTS AND METHODS OF USE

#2 | 2026-04-23

US20260109690A1

HDAC6 INHIBITORS AND METHOD OF THEIR USE

#3 | 2026-02-19

US20260049086A1

CDK9 INHIBITORS

#4 | 2025-12-25

US20250388571A1

AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF

#5 | 2025-04-10

US20250114357A1

BIFUNCTIONAL PROTAC AND MOLECULAR GLUE COMPOUNDS AND METHODS OF USE THEREOF

#6 | 2024-11-21

US20240382473A1

Combination Therapies for Treatment of Myelodysplastic Syndrome

#7 | 2024-05-09

US20240150322A1

CDK9 Inhibitors

#8 | 2024-03-14

US20240083855A1

JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE

#9 | 2024-03-07

US20240075033A1

ALK5 INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROME

#10 | 2023-10-12

US20230322792A1

CDK9 inhibitors

#11 | 2023-06-01

US20230165857A1

AXL KINASE INHIBITORS AND USE OF THE SAME

#12 | 2022-10-27

US20220339172A1

METHODS FOR TREATING CASTRATION-RESISTANT AND CASTRATION-SENSITIVE PROSTATE CANCER

#13 | 2022-09-29

US20220305037A1

Treatment of Cancer

#14 | 2022-08-18

US20220257581A1

Treatment of Cancer

#15 | 2022-04-28

US20220125776A1

Treatment of acute myeloid leukemia (AML) with venetoclax failure

#16 | 2021-08-26

US20210261585A1

Alvocidib Prodrugs Having Increased Bioavailability

#17 | 2021-07-08

US20210205304A1

AXL kinase inhibitors and use of the same

#18 | 2021-05-20

US20210145830A1

MATERIALS AND METHODS FOR TREATING CANCER

#19 | 2021-03-11

US20210070715A1

JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE

#20 | 2021-02-25

US20210052568A1

PREDICTING RESPONSE TO ALVOCIDIB BY MITOCHONDRIAL PROFILING

#21 | 2021-01-07

US20210000825A1

Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

#22 | 2020-10-15

US20200323851A1

ALK5 INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROME

#23 | 2020-10-08

US20200316084A1

METHODS TO TARGET TRANSCRIPTIONAL CONTROL AT SUPER-ENHANCER REGIONS

#24 | 2020-09-24

US20200297698A1

Compositions comprising PKM2 modulators and methods of treatment using the same

#25 | 2020-09-10

US20200281949A1

METHODS FOR TREATING CASTRATION-RESISTANT AND CASTRATION-SENSITIVE PROSTATE CANCER

#26 | 2020-09-03

US20200276215A1

Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib

#27 | 2020-09-03

US20200276174A1

CYCLIN-DEPENDENT KINASE INHIBITORS IN COMBINATION WITH ANTHRACYCLINES FOR TREATMENT OF CANCER

#28 | 2020-07-30

US20200237766A1

PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER

#29 | 2020-06-25

US20200200737A1

PROFILING PEPTIDES AND METHODS FOR SENSITIVITY PROFILING

#30 | 2020-04-30

US20200131210A1

ALVOCIDIB PRODRUGS HAVING INCREASED BIOAVAILABILITY

#31 | 2020-03-19

US20200085823A1

Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same

#32 | 2019-10-17

US20190314357A1

CYCLIN-DEPENDENT KINASE INHIBITORS IN COMBINATION WITH ANTHRACYCLINES FOR TREATMENT OF CANCER

#33 | 2019-09-19

US20190282557A1

Predicting response to alvocidib by mitochondrial profiling

#34 | 2019-06-13

US20190178873A1

Profiling peptides and methods for sensitivity profiling

#35 | 2019-06-13

US20190177350A1

Alvocidib prodrugs having increased bioavailability

#36 | 2019-04-25

US20190119221A1

JAK1 and ALK2 inhibitors and methods for their use

#37 | 2019-01-31

US20190030017A1

Predicting response to alvocidib by mitochondrial profiling

#38 | 2018-10-18

US20180299432A1

Profiling peptides and methods for sensitivity profiling

#39 | 2018-10-04

US20180280407A1

METHODS TO TARGET TRANSCRIPTIONAL CONTROL AT SUPER-ENHANCER REGIONS

#40 | 2018-09-13

US20180256580A1

Combination therapies for treatment of cancer

#41 | 2018-06-21

US20180172673A1

Profiling peptides and methods for sensitivity profiling

#42 | 2018-05-17

US20180134719A1

SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS

#43 | 2017-11-23

US20170334938A1

Alvocidib prodrugs having increased bioavailability

#44 | 2016-11-24

US20160340376A1

Alvocidib prodrugs having increased bioavailability

#45 | 2016-10-20

US20160303101A1

Predicting response to alvocidib by mitochondrial profiling

#46 | 2016-07-28

US20160214944A1

JAK2 and ALK2 inhibitors and methods for their use

#47 | 2016-05-05

US20160120875A1

Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors

#48 | 2016-02-18

US20160046586A1

SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS

#49 | 2015-12-24

US20150368208A1

Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

#50 | 2015-09-10

US20150252048A1

Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

#51 | 2015-06-04

US20150150864A1

Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors

#52 | 2015-01-15

US20150018349A1

Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

#53 | 2014-06-12

US20140163017A1

Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors

#54 | 2014-04-03

US20140094445A1

Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors

#55 | 2013-03-07

US20130059847A1

Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

#56 | 2012-11-08

US20120283261A1

Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase

#57 | 2012-11-01

US20120277229A1